INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt...

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, ...

INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer'...

INmune Bio Inc. Announces Third Quarter 2024 Results and Provides Business Update...

INmune Bio Inc. to Host Webinar on Cognitive Testing Using EMACC and CDR-SB...

INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Octob...

INmune Bio Inc. Announces Publication in Cell Reports Demonstrating XPro™ Promotes Remyelination...

INmune Bio Inc. to Participate in the Maxim Healthcare Virtual Summit...

INmune Bio Inc. Completes Enrollment for Phase 2 Trial in Early Alzheimer's Disease...

INKmune™ Demonstrates Excellent Safety and Increased NK-Cell Activity in First Dosing Cohort...

INmune Bio Announces Results of Additional Blinded Interim Analysis of Phase 2 Alzheimer's Dise...

INmune Bio Announces $13.0 Million Registered Direct Offering...

INmune Bio Inc. to Present at the Baird 2024 Global Healthcare Conference...

INmune Bio Inc. Announces Second Quarter 2024 Results and Provides Business Update...

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on P...

INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Th...

INmune Bio Inc. Publishes Novel Biology on Natural Killer Cancer Immunotherapy INKmune™ in the Jou...

INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial...

INmune Bio Inc. to Join Russell 3000® Index...

INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business Update...

INmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thu...

INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Co...

INmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ ...

INmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq ...

INmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Comme...

INmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offeri...

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment ...

INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Update...

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Th...

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell...

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™...

INmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference...

INmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024...

INmune Bio: FDA Removes Clinical Hold For Alzheimer's Disease Program...

INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune™ in Patients with Metasta...